41 results on '"McDonnell, Timothy J."'
Search Results
2. High-grade B-cell lymphoma (HGBL)-NOS is clinicopathologically and genetically more similar to DLBCL/HGBL-DH than DLBCL
3. A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL
4. Lymphoplasmacytic lymphoma with IgG or IgA paraprotein: a study of 29 cases including cases that can mimic plasma cell neoplasms
5. EZH2 expression is associated with inferior overall survival in mantle cell lymphoma
6. Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysis
7. The Irish national chronic obstructive pulmonary disease quality improvement collaborative: an adaptive learning collaborative
8. Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy
9. The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes.
10. Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP
11. Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors
12. B-acute lymphoblastic leukemia/lymphoma (B-ALL) with precedent or concurrent myelodysplastic syndrome (MDS) with deletion 5q
13. Supplementary Figures 1-4 from The RB-E2F1 Pathway Regulates Autophagy
14. Data from The RB-E2F1 Pathway Regulates Autophagy
15. High-grade B-cell lymphoma (HGBL)-NOS is clinicopathologically and genetically more similar to DLBCL/HGBL-DH than DLBCL
16. Evaluating the Impact of Lab-Based Eligibility Criteria By Race/Ethnicity in Frontline Clinical Trials for Diffuse Large B-Cell Lymphoma (DLBCL): A LEO Cohort Analysis
17. Comparison of outpatient and home‐based exercise training programmes for COPD: A systematic review and meta‐analysis
18. Pure erythroid leukemia is characterized by biallelic TP53 inactivation and abnormal p53 expression patterns in de novo and secondary cases
19. Clinical Validation of MCL35 in Mantle Cell Lymphoma Patients ≥65 Years Receiving Bendamustine-Rituximab
20. Diagnosis to Treatment Interval (DTI) Informs Outcomes across Subtypes of Aggressive B-Cell Lymphoma
21. Real-World Impact of Differences in the World Health Organization (WHO) Classification and International Consensus Classification (ICC) Systems on the Diagnosis of Non-Hodgkin Lymphoma: An Analysis from the LEO Cohort Study
22. A 34-Year-Old Man With a Chylothorax and Bony Pain
23. MYCrearrangement and MYC/BCL2 double expression but not cell‐of‐origin predict prognosis in R‐CHOP treated diffuse large B‐cell lymphoma
24. Smart Start: Rituximab, Lenalidomide, and Ibrutinib Alone and in Combination with Standard Chemotherapy for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Final Phase II Results
25. Utility and Patterns of Use of PET/CT and Bone Marrow Biopsy for Staging in Non-Hodgkin Lymphoma in the Clinical Setting: A Retrospective Analysis Using the LEO Database
26. Flex-Array® – a novel multi-well vessel system for the immobilization and multi-modal testing of intact formalin-fixed paraffin-embedded (FFPE) cells or tissues
27. ‘When you hear hooves, think zebras, not horses’; two challenging cases of interstitial lung disease (ILD)
28. A 34-Year-Old Man With a Chylothorax and Bony Pain.
29. MYC rearrangement and MYC/BCL2 double expression but not cell‐of‐origin predict prognosis in R‐CHOP treated diffuse large B‐cell lymphoma.
30. The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study Reflects the Demographics and Subtypes of Patients Diagnosed with Non-Hodgkin Lymphoma in the United States
31. Comparison of outpatient and home-based exercise training programmes for COPD: A systematic review and meta-analysis
32. High Risk Diffuse Large B Cell Lymphoma: A Comparison of Aggressive Subtypes Treated with Dose Adjusted Chemotherapy-the University of Texas MD Anderson Experience
33. Analyzing Patient Characteristics Who Received (DA) EPOCH-R for High Risk Diffuse Large B-Cell Lymphoma: MD Anderson Cancer Center Experience
34. Lenalidomide and Obinutuzumab with CHOP for Newly Diagnosed Diffuse Large B-Cell Lymphoma: Phase I Results
35. Case of coccidioidomycosis in Ireland
36. ONC201 Induces p53-Independent Apoptosis and Abrogates Stem Cell Function in Hematological Malignancies By Induction of ATF4 through Integrated Stress Response
37. MYC Signatures and Characterization of MYC-Driven Aggressive B-Cell Lymphoma
38. Defining exacerbations in chronic obstructive pulmonary disease
39. Lenalidomide and Obinutuzumab with CHOP for Newly Diagnosed Diffuse Large B-Cell Lymphoma: Final Phase I/II Results
40. Clinical features, tumor biology, and prognosis associated with MYCrearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP
41. 'When you hear hooves, think zebras, not horses'; two challenging cases of interstitial lung disease (ILD).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.